|1.||Pollak, Michael N: 23 articles (07/2015 - 09/2003)|
|2.||Baxter, Robert C: 21 articles (09/2015 - 05/2002)|
|3.||Pollak, Michael: 19 articles (02/2015 - 07/2002)|
|4.||Kaaks, Rudolf: 18 articles (07/2013 - 02/2004)|
|5.||Cohen, Pinchas: 17 articles (02/2013 - 06/2002)|
|6.||Yu, Herbert: 17 articles (11/2011 - 08/2002)|
|7.||Holly, Jeff M P: 16 articles (08/2013 - 11/2002)|
|8.||Riboli, Elio: 15 articles (07/2013 - 01/2005)|
|9.||Trichopoulos, Dimitrios: 13 articles (07/2013 - 01/2003)|
|10.||Rinaldi, Sabina: 13 articles (10/2011 - 08/2004)|
01/01/2005 - "Although IGFBP-3 expression was not an independent prognosticator, IGFBP-3-positive breast cancers may have shorter disease-free and overall survivals, although these did not reach statistical significance. "
01/01/2004 - "HeLa cells expressing ectopic IGFBP-3 or DKK-1 showed statistically significant differences in the kinetics of tumor formation. "
09/10/2015 - "Nuclear IGFBP-3 can be detected by immunohistochemistry in cancer and other tissues, and its presence in the nucleus has been shown in many cell culture studies to be necessary for its pro-apoptotic effect, which may also involve interaction with the nuclear receptor Nur77, and export from the nucleus. "
09/01/2011 - "Future studies are needed for development of IGFBP-3 as a new line of antiangiogengic cancer drug."
09/24/2010 - "Recent epidemiologic studies suggest that IGFBP-3 contributes to cancer risk protection in a variety of cancers, and a polymorphic variation of IGFBP-3 influences cancer risk, although other studies vary in their conclusions. "
03/01/2002 - "In addition, a detailed review of the literature suggests that IGFBP-3 measurements may be helpful in confirming the diagnosis of concurrent acromegaly and distinguishing it from high GH levels attributable to poor control of diabetes."
11/01/1998 - "IGFBP-3 levels were significantly higher in subjects with active acromegaly (4940 +/- 301 microg/L) vs. those in healthy subjects (2887 +/- 153 microg/L; P < 0.0001) and those in the subjects in remission (2966 microg/L; P < 0.0001). "
03/01/2005 - "Serum IGFBP-3 measurements are useful for diagnostic evaluations of short stature in children and acromegaly. "
10/17/1999 - "[The role of insulin-like-growth-factor-binding protein 3 in the evaluation of disease activity in acromegaly]."
01/01/1998 - "Serum IGFBP-3 in patients with pituitary acromegaly does not provide a predictive value of appreciable magnitude concerning cure or non-cure from the disease- whether examined early or late in the post-operative period. "
|3.||Breast Neoplasms (Breast Cancer)
04/01/2004 - "These findings suggest that the interaction between IGFBP-3 and the EGFR system is central to whether IGFBP-3 acts as a growth stimulator or inhibitor in breast cancer cells and that therapies targeting EGFR may have increased efficacy in breast tumors expressing high levels of IGFBP-3."
01/01/1996 - "In the present study, cultured MCF-7 breast cancer regulated clearance of IGFBP-3 via both cell association and proteolysis. "
10/01/2014 - "These pro-apoptotic properties, however, do not correlate with several studies linking high IGFBP-3 levels in breast cancer tissue to rapid growth and poor prognosis. "
06/01/2011 - "In this study, associations between single nucleotide polymorphisms (SNPs) and diplotypes in the IGFBP1 and IGFBP3 genes and circulating IGFBP-3 levels, BRCA family status and breast cancer among women from high-risk breast cancer families were investigated. "
12/01/2009 - "This study examined the effects of endogenous IGFBP-3 in Hs578T breast cancer cells, which are IGF-unresponsive and grow aggressively despite relatively high IGFBP-3 expression. "
|4.||Prostatic Neoplasms (Prostate Cancer)
04/01/2007 - "We hypothesize that the protective effects of VES in prostate cancer are mediated by IGFBP-3 up-regulation. "
05/15/2009 - "For all exposures, there was substantial heterogeneity (all I(2) > 75%), partly explained by study design: the magnitude of associations was smaller in prospective vs. retrospective studies, and for IGFBP-3, the inverse association with prostate cancer risk was seen in retrospective but not prospective studies. "
11/15/2006 - "These studies reveal a novel regulatory mechanism for the actions of IGFBP-3 in prostate cancer and show phosphorylation of Ser(156) to be functionally critical in its apoptosis-inducing actions."
06/15/2005 - "Our studies indicate 1,25D-induced up-regulation of IGFBP-3 is not required for the growth inhibitory effects of 1,25D in prostate cancer cells grown in serum-containing media."
05/01/2002 - "In this study, we evaluated the role of endogenous IGFBP-3 on prostate cancer cell growth and tumorigenesis. "
12/01/2014 - "We found that ocular blast alone did not affect IGFBP-3 levels in retinas of wild type or knockdown mice and surprisingly, the lower levels of IGFBP-3 in knockdown animals did not exacerbate the blast-induced increase in protein levels of inflammation/apoptosis markers. "
01/31/2003 - "These data indicate that acute inflammation inhibits serum concentrations of IGFBP-3 by decreasing its synthesis in the liver, rather than increasing its proteolysis. "
01/01/1994 - "Inflammation may inhibit bone formation via decreased serum levels of IGFs and blocked IGFBP-3 response to PTH."
12/01/2014 - "Nevertheless, the levels of IGFBP-3 were significantly increased in knockdown mouse retina by treatment with Compound 49b 24h post-trauma and as expected, the increase in IGFBP-3 was linked to a decrease in inflammation/apoptosis markers. "
04/01/2014 - "The regulatory roles of IGFBP-3 in inflammation and bone destruction were investigated in mice with collagen-induced arthritis (CIA). "
|1.||Insulin-Like Growth Factor I (IGF-1)
|3.||Insulin-Like Growth Factor II (Somatomedin A)
|4.||Carrier Proteins (Binding Protein)
|6.||Prostate-Specific Antigen (Semenogelase)
|8.||Adrenergic Agonists (Adrenergic Receptor Agonist)
|9.||Insulin-Like Growth Factor Binding Protein 1
|10.||Insulin-Like Growth Factor Binding Proteins
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Hormone Replacement Therapy (Therapy, Hormone Replacement)